Workshops & Seminars

  • Home
  • Workshops & Seminars

Planova™ Workshops and Local Seminars

The Planova Workshop is an opportunity for Planova users to share experiences and to learn the best practices of virus filtration. Event chairs and speakers at this annual event are key industry leaders in biotherapeutics, and their presentations cover topics such as tips for process optimization, validations, regulatory requirements and scaling up to commercial manufacturing. Event attendees include experts in the fields of regulation, process development, pathogen safety, quality and manufacturing. Since the first Planova Workshop held in 1998 in Oslo, Norway, this annual event has greatly contributed to raising awareness on viral safety as well as effective use of virus filtration in the manufacturing processes of biotherapeutics.

Planova Local Seminars are similar events tailored to the needs of certain local regions, with additions of presentations covering case studies from global and local companies as well as regulatory updates on viral safety specific to the region.

In this Page, you can explore details of the upcoming events as well as download materials available from past events (login required).

Upcoming Events

Below you can find details of the upcoming events, including registration forms once they are available.

The 3rd Planova™ Seminar in Moscow

Nov 19, 2018
Moscow, Russia

Latest Workshops

Below you can find details of the last five Planova Workshops and download the presentation materials (login required). To find information on other previous Planova Workshops, click Archive.

Latest Seminars

Below you can find details of the last five Local Seminars and download the presentation materials (login required). To find information on other previous Local Seminars, click Archive.

Search Presentations

Here you can search and download (login required) presentation materials from past Planova Workshops, by entering keyword or by using filters for each category.

Keyword

Filter by Protein Type

Filter by Contents

Filter by Products

You need to log in to download the files.

141 Results Found

  1. 10
  2. 20
  3. 30
  4. All
  1. Consistent and Reliable 100% Retrovirus Removal by Planova™ 20N filter: Demonstration of Robust Log Reduction (>6.0) by Co-spiking Study

    Dayue Chen, Virology Group Bioprocess Research and Development, Eli Lilly and Company
    14th Planova™ Workshop
    Nov 9, 2011 to Nov 10, 2011
    Cologne

  2. Virus Inactivation at Low pH: Impact of Buffers, pH Value, Protein Concentration and Temperature on the Inactivation of Retroviruses

    Michael Dieterle, Associate Director Downstream Development, Boehringer Ingelheim GmbH&Co.KG
    14th Planova™ Workshop
    Nov 9, 2011 to Nov 10, 2011
    Cologne

  3. Implementation of Quality by Design to Nanofiltration of Plasma Products

    Monique Ollivier, Director, Process Development-Downstream & Analytics, Cytheris S.A.
    14th Planova™ Workshop
    Nov 9, 2011 to Nov 10, 2011
    Cologne

  4. FULL PLASTICS for a 1000L Disposable Production Line for Generic Antibody Manufacturing

    Peter Rogge, Director, DSP Production, Rentschler Biotechnologie GmbH
    14th Planova™ Workshop
    Nov 9, 2011 to Nov 10, 2011
    Cologne

  5. New Concept of Integrity Test for Planova™ BioEX

    Shinya Sekine, Manager, Technology Development Department, Asahi Kasei Medical Co., Ltd.
    14th Planova™ Workshop
    Nov 9, 2011 to Nov 10, 2011
    Cologne

  6. PDA Technical Report 41: Virus Filtration - History and the Future

    Kurt Brorson, Staff Scientist, CDER, FDA
    15th Planova™ Workshop
    Jun 14, 2012 to Jun 15, 2012
    Boston

  7. The Purity of Virus Spikes: Influences on the Performance of Virus Removal Filters

    Joseph Hughes, Chief Scientist of Virology and Vice President for Service Development, WuXi AppTec, Inc.
    15th Planova™ Workshop
    Jun 14, 2012 to Jun 15, 2012
    Boston

  8. Viral Filtration of Enzyme Therapeutics Using Planova™ 15N and Planova™ 20N filters

    Mei Huei Jang, Senior Scientist, Purification Process Development, Shire Pharmaceuticals
    15th Planova™ Workshop
    Jun 14, 2012 to Jun 15, 2012
    Boston

  9. Integrity Testing of Planova™ BioEX Virus Removal FiltersBioEX Virus Removal Filters

    Shinya Sekine, Manager, Technology Development Department Bioprocess Division, Asahi Kasei Medical Co., Ltd.
    15th Planova™ Workshop
    Jun 14, 2012 to Jun 15, 2012
    Boston

  10. Filtration Robustness of Planova™ BioEX Virus-Removal Filter

    Tomoko Hongo-Hirasaki, Manager, Technology Development Department, Bioprocess Division, Asahi Kasei Medical Co., Ltd.
    15th Planova™ Workshop
    Jun 14, 2012 to Jun 15, 2012
    Boston

  11. Plasma Derivatives and Virus Safety: Relevant Regulations and Guidelines - An Industry Perspective -

    Herbert Dichtelmüller, ViruSafe-Consult
    1st Planova™ Workshop in India
    Jan 31, 2013
    Goa

  12. Planova™ Filters - Virus Removal from Biotherapeutic Products -

    Ravinder Dabas, Manager, Asahi Kasei India Private Limited
    1st Planova™ Workshop in India
    Jan 31, 2013
    Goa

  13. Validation of Virus Filtration Steps - Practical Aspects for Optimization of the Study Design Leading to Optimal Results -

    Olaf Stamm, Senior Specialist, Biopharmaceutical Services, Charles River
    1st Planova™ Workshop in India
    Jan 31, 2013
    Goa

  14. Preparation of Plasma Meeting Requirements for Contract or Domestic Fractionation

    Thierry Burnouf, Director, Human Protein Process Sciences
    1st Planova™ Workshop in India
    Jan 31, 2013
    Goa

  15. Plasma Fractionation - Current Technologies and New Trends -

    Sami Chtourou, Senior Vice President, Innovation and Scientific Affairs, LFB Biotechnologies
    1st Planova™ Workshop in India
    Jan 31, 2013
    Goa

  16. Biotherapeutics and Virus Safety: Relevant Regulations and Guidelines

    Herbert Dichtelmüller, ViruSafe-Consult
    1st Planova™ Workshop in India
    Jan 31, 2013
    Goa

  17. Application of Planova™ Virus Filters in MAb Purification Processes - Impact on Virus Safety and Process Performance -

    Franz Nothelfer, Associate Director, Purification Development, Boehringer Ingelheim Pharma GmbH & Co. KG
    1st Planova™ Workshop in India
    Jan 31, 2013
    Goa

  18. Improvement of MAb Production Cost

    Sami Chtourou, Senior Vice President, Innovation and Scientific Affairs, LFB Biotechnologies
    1st Planova™ Workshop in India
    Jan 31, 2013
    Goa

  19. Ensuring Viral Safety in Recombinant Biotherapeutics

    Sudip Kumar Majumder, Principal Scientist & Head, Downstream Process Development, Intas Biopharmaceuticals Limited
    1st Planova™ Workshop in India
    Jan 31, 2013
    Goa

  20. Investigations of PCV Removal by Planova™ 15N Filters and Planova™ Filters with Pore Size Smaller than 15 nm

    Natascha Hodosi, GLP Study Director, ViruSure
    17th Planova™ Workshop
    Jun 12, 2014 to Jun 13, 2014
    Washington, D.C.

  21. Asahi Gold Particle Test System Development and Implementation Case Study

    Kimo Sanderson, Vice President, Client Services, Asahi Kasei Bioprocess
    17th Planova™ Workshop
    Jun 12, 2014 to Jun 13, 2014
    Washington, D.C.

  22. Use of Porcine Circovirus as a Challenge for Filtration and Other Virus Risk Mitigation Steps

    Kathryn Martin Remington, Principal Scientist, Clearance Services, BioReliance
    17th Planova™ Workshop
    Dec 12, 2014 to Dec 13, 2014
    Washington, D.C.

  23. Virus Filtration and Biotechnology Processes

    Thomas Kreil, Associate Professor of Virology at the Medical University of Vienna and Senior Director, Global Pathogen Safety, Baxter BioScience
    17th Planova™ Workshop
    Jun 12, 2014 to Jun 13, 2014
    Washington, D.C.

  24. Perspective of Plasma-Derived Products in China

    LIU Wenfang, Professor, Institute of Blood Transfusion, Chinese Academy of Medical Sciences/ Peking Union Medical College
    1st Planova™ Workshop in China
    Jan 15, 2015
    Hainan Island

  25. Pathogen Safety of Biological Medicinal Products

    Thomas R.KREIL, Associate Professor of Virology, Senior Director Global Pathogen Safety, BaxterBioScience
    1st Planova™ Workshop in China
    Jan 15, 2015
    Hainan Island

  26. State of the Art Approaches to Ensure Pathogens Safety of Plasma-Derived Products -an Industry Perspective

    Thierry BURNOUF, Director, Graduate Institute of Biomedical Materials and Tissue Engineering, Taipei Medical University, Taiwan
    1st Planova™ Workshop in China
    Jan 15, 2015
    Hainan Island

  27. Planova™ Filters: Virus Removal from Bio-therapeutic Products

    LIU Zhanjie, Deputy Manager of Shanghai Representative Office, Bioprocess Division, Asahi Kasei China Co., Ltd., China
    1st Planova™ Workshop in China
    Jan 15, 2015
    Hainan Island

  28. Validation of Virus Filtration Steps

    Joseph V. HUGHES, Chief Scientist, Virology, Vice President- Technical Development, WuXi AppTec Inc.
    1st Planova™ Workshop in China
    Jan 15, 2015
    Hainan Island

  29. Blood Products Safety and Regulation in China

    HOU Jifeng, Head of Blood Products Division, National Institutes for Food and Drug Control
    1st Planova™ Workshop in China
    Jan 15, 2015
    Hainan Island

  30. State of the Art of the IVIG Manufacturing

    Sami CHTOUROU, Executive Vice President, Innovation & Scientific Affairs, LFB Biotechnologies
    1st Planova™ Workshop in China
    Jan 15, 2015
    Hainan Island

  31. Virus Safety in Blood Plasma-Derived Products-Planova™ Virus Filtration

    XU Tan, Project Manager, Research and Development Division, Chengdu Rongsheng Pharmaceuticals Co., Ltd.
    1st Planova™ Workshop in China
    Jan 15, 2015
    Hainan Island

  32. Current Situation of Viral Clearance for Biological Products in China

    FU Rui, Vice Senior Investigator, Division of Laboratory Animal Monitoring, National Institutes for Food and Drug Control
    1st Planova™ Workshop in China
    Jan 15, 2015
    Hainan Island

  33. State of the Art Manufacturing of Biotechnological Products

    Albrecht GROENER, Head Pathogen Safety, CSL Behring
    1st Planova™ Workshop in China
    Jan 15, 2015
    Hainan Island

  34. Asahi Kasei Medical Product Development Concept

    MIYABAYASHI Tomoyuki, General Manager, Technical Marketing Department, Asahi Kasei Medical Co., Ltd.
    1st Planova™ Workshop in China
    Jan 15, 2015
    Hainan Island

  35. Optimization of Virus Removal Filtration Processes: Design of Process Parameters and Virus Validation Studies

    Tomoko HONGO-HIRASAKI, Manager, Technology Development, Bioprocess Division, Asahi Kasei Medical
    18th Planova™ Wokshop
    Oct 22, 2015 to Oct 23, 2015
    Athens

  36. Virus filtration studies and manufacturing processes: does equivalence need a fresh look?

    Andreas WIESER, Senior Laboratory Associate, Global Pathogen Safety, Baxalta
    18th Planova™ Wokshop
    Oct 22, 2015 to Oct 23, 2015
    Athens

  37. Robustness of 15 or 20 nm filtration in manufacturing processes of plasma derived medicinal products

    Anky KOENDERMAN, Staff member, R&D unit, Sanquin Plasma Products bv
    18th Planova™ Wokshop
    Oct 22, 2015 to Oct 23, 2015
    Athens

  38. Defining the Design Spaces for Robust Viral Clearance in Planova™ 20N and BioEX Filter Processes

    Daniel STRAUSS, Senior Scientist, Science and Technology, Asahi Kasei Bioprocess America
    18th Planova™ Wokshop
    Oct 22, 2015 to Oct 23, 2015
    Athens

  39. Use of MF-SL and Planova™ 20N in the Factor V manufacturing process in Kedrion

    Silvia NANNIZZI, Scientist, Industrial Development and Research, Kedrion Spa
    18th Planova™ Wokshop
    Oct 22, 2015 to Oct 23, 2015
    Athens

  40. Development of an Improved Downstream Process for Tissue Plasminogen Activator: Implementing QyuSpeed D and Planova™ BioEX

    Franz NOTHELFER, Associate Director Protein Science, Biopharmaceuticals, Process Development, Boehringer Ingelheim Pharma GmbH & Co. KG
    18th Planova™ Wokshop
    Oct 22, 2015 to Oct 23, 2015
    Athens

  41. Optimization of the Nanofiltration Step within the Manufacturing Process of the Coagulation Factor IX

    Eckhard FLECHSIG, Senior Director Pathogen Safety, Global Research, Biotest AG
    18th Planova™ Wokshop
    Oct 22, 2015 to Oct 23, 2015
    Athens

  42. Virus Filtration Scalability: Demonstration of Virus Removal Consistency from Small Scale to Manufacturing Scale

    Brian BUESING, Research Associate, Science and Technology, Asahi Kasei Bioprocess America, Inc.
    18th Planova™ Wokshop
    Oct 22, 2015 to Oct 23, 2015
    Athens

  43. Planova™ Filter in the Production Process of a Gene Therapy Product

    Leila DIAS, Scientist DSP, Process Development, uniQure N.V.
    18th Planova™ Wokshop
    Oct 22, 2015 to Oct 23, 2015
    Athens

  44. Nanofiltration on Culture Media to Secure Cell and Viral Banks

    Landry BERTAUX, Cell and viral culture Scientist, Bioprocess R&D, Sanofi Pasteur
    18th Planova™ Wokshop
    Oct 22, 2015 to Oct 23, 2015
    Athens

  45. Approach for Phage Risk Mitigation Using Virus Filter

    Simon HAIDINGER, Head of Upstream Development I, Biopharmaceuticals Process Science Austria, Boehringer Ingelheim RCV GmbH & Co KG
    18th Planova™ Wokshop
    Oct 22, 2015 to Oct 23, 2015
    Athens

  46. Development of a 20 nm Nanofiltration Step for High Purity Fibrinogen Manufacturing Process

    Salvador GRANCHA, Vice-president Research & Development, R&D, Bioscience Industrial Group, Grifols
    18th Planova™ Wokshop
    Oct 22, 2015 to Oct 23, 2015
    Athens

  47. Highly Effective and Robust Virus Filtration Design for Early Phase and Commercial Processes

    Nathan J ROTH, Director/Head Global Pathogen Safety, R&D, CSL Behring
    18th Planova™ Wokshop
    Oct 22, 2015 to Oct 23, 2015
    Athens

  48. Determination of Viral Clearance Design Spaces on Planova™ 20N and BioEX filters - Low Pressure Limits

    Josh Goldstein, Senior Scientist, API-LM, Pharmaceutical Development and Manufacturing Sciences, Janssen Research & Development, LLC
    19th Planova™ Workshop
    Sep 22, 2016 to Sep 23, 2016
    Philadelphia

  49. Scalability of Planova™ BioEX Filters

    Daniel Strauss, Senior Scientist, Science and Technology, Asahi Kasei Bioprocess America, Inc.
    19th Planova™ Workshop
    Sep 22, 2016 to Sep 23, 2016
    Philadelphia

  50. Filtration Study to Remove Mycoplasma Acholeplasma laidlawii with Planova™ 20N and BioEX Filters

    Masayasu Takahara, Manager, Technical Marketing, Bioprocess, Asahi Kasei Medical Co., Ltd.
    19th Planova™ Workshop
    Sep 22, 2016 to Sep 23, 2016
    Philadelphia

  51. Fine Tuning Viral Clearance Approaches with a Total Viral Load Strategy

    Michael Burnham, Director, Purification and Process Development, WuXi AppTec, Inc.
    19th Planova™ Workshop
    Sep 22, 2016 to Sep 23, 2016
    Philadelphia

  52. Effects of Pressure and Process Pausing on Viral Removal During Viral Filtration

    Sean O'Donnell, Senior Research Scientist, Virology and Purification Development, Eli Lilly and Company
    19th Planova™ Workshop
    Sep 22, 2016 to Sep 23, 2016
    Philadelphia

  53. Pressure and Flow Variations, Filter Integrity Testing: Robustness Questions Answered?

    Thomas R. Kreil, Associate Professor of Virology, Senior Director, Global Pathogen Safety, Shire
    19th Planova™ Workshop
    Sep 22, 2016 to Sep 23, 2016
    Philadelphia

  54. Asahi Gold Particle Test System (AGPTS) : Confidence in Automation

    Michael Proctor, Manager, Zemaira Manufacturing, CSL Behring
    19th Planova™ Workshop
    Sep 22, 2016 to Sep 23, 2016
    Philadelphia

  55. Planova™ 35N Nanofiltration of a Plasma-Derived Immune Globulin Product

    Barry D. Gooch, Section Head of Pathogen Safety Development & Validation, R&D Bioscience Industrial Group, North Carolina R&D, Grifols, Inc.
    19th Planova™ Workshop
    Sep 22, 2016 to Sep 23, 2016
    Philadelphia

  56. Effective and Robust Virus Filtration

    Nathan J. Roth, Senior Director & Head Global Pathogen Safety, CSL Behring
    19th Planova™ Workshop
    Sep 22, 2016 to Sep 23, 2016
    Philadelphia

  57. Robust Virus Filtration Processes: Protein Filterability and Viral Clearance

    Tomoko Hongo-Hirasak, Manager, Technology Development, Bioprocess, Asahi Kasei Medical
    19th Planova™ Workshop
    Sep 22, 2016 to Sep 23, 2016
    Philadelphia

  58. Evaluation of Virus Filtration Operation, Scale Up and Validation for a Fusion Protein

    Dharmesh Kanani, Senior Scientist, Downstream Process Development & Operations, Global CMC Biologics, Teva Biopharmaceuticals
    19th Planova™ Workshop
    Sep 22, 2016 to Sep 23, 2016
    Philadelphia

  59. Screening, Scale-Up and Validation of Virus Filtration for Aggregatable mAb Product

    Dong-Woo Lee, Manager, Purification Process Team / R&D Center, Celltrion, Inc.
    19th Planova™ workshop
    Sep 22, 2016 to Sep 23, 2016
    Philadelphia

  60. Evaluation of Asahi Planova™ BioEX Viral Filter Used in Therapeutic Antibody Manufacturing Processes

    Shengjiang Shawn Liu, Head and Chief Scientist, Pathogen Safety, Biological Development, Bayer HealthCare Pharmaceuticals
    19th Planova™ Workshop
    Sep 22, 2016 to Sep 23, 2016
    Philadelphia

  61. Pathogen Safety Concepts for Biotechnology: from Plasma Products, to Recombinant Proteins, to Advanced Therapy Medicinal Products

    Thomas R. Kreil, Associate Professor of Virology Senior Director Global Pathogen Safety, Shire
    2nd Planova™ Workshop in India
    Feb 9, 2017
    Goa

  62. Defining the Design Spaces for Robust Viral Clearance in Planova™ 20N and BioEX Processes

    Daniel Strauss, Senior Scientist Science and Technology, Asahi Kasei Bioprocess America, Inc.
    2nd Planova™ Workshop in India
    Feb 9, 2017
    Goa

  63. Virus Retentive Filtration 2017- Regulatory Expectations and Challenges

    Horst Ruppach, Global Director Viral Clearance and Virology Charles River, Biologics Testing Solutions
    2nd Planova™ Workshop in India
    Feb 9, 2017
    Goa

  64. A General Mechanistic Model for Viral Filtration

    Anupam Shukla, Associate Professor Department of Chemical Engineering, Indian Institute of Technology Delhi
    2nd Planova™ Workshop in India
    Feb 9, 2017
    Goa

  65. Current Technologies for Human Plasma-Derived Products

    Thierry Burnouf, Director and Professor, Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University
    2nd Planova™ Workshop in India
    Feb 9, 2017
    Goa

  66. Manufacturing Biopharmaceuticals and Biologicals: Current Trends, Challenges and Technology Drivers

    Sandeep B. Kale, Deputy Coordinator of DBT-ICT-Centre for Energy Biosciences Associate Professor & Co-ordinator for M. Tech. Program, Institute of Chemical Technology
    2nd Planova™ Workshop in India
    Feb 9, 2017
    Goa

  67. Implementing Nano Filtration for Platform Manufacturing of Monoclonal Antibodies

    Girish M. Masand, Deputy General Manager, Therapeutic Proteins - Process Development, Reliance Life Sciences Pvt Ltd.
    2nd Planova™ Workshop in India
    Feb 9, 2017
    Goa

  68. From Lab to Production Scale: Challenges and Implementation of Virus Removal Filters in Large-scale GMP-manufacturing

    Christian Koch, Senior Transfer Engineer, Product Transfer & Process Engineering - Protein Purification, Boehringer lngelheim Pharma GmbH & Co. KG
    2nd Planova™ Workshop in India
    Feb 9, 2017
    Goa

  69. Screening, Scale-Up and Validation of Virus Filtration for Aggregatable mAb Product

    Dong-Woo Lee, Manager, Purification Process Team / R&D Center, Celltrion, Inc.
    2nd Planova™ Workshop in India
    Feb 9, 2017
    Goa

  70. A Review of Virus Filter Performance ‒ Critical Process Parameters and Best Practice

    Horst Ruppach, Global Director, Viral Clearance and Virology, Charles River
    20th Planova™ Workshop
    Nov 9, 2017 to Nov 10, 2017
    Prague

  71. Differential Retention of Parvoviruses During Virus Filtration

    Thomas Nowak, Senior Manager, Virus Safety Development R&D, CSL Behring
    20th Planova™ Workshop
    Nov 9, 2017 to Nov 10, 2017
    Prague

  72. Introduction of a Nanofiltration Step in FVIII Purification Process

    Filippo Mori, Senior Researcher, Research Department, Kedrion
    20th Planova™ Workshop
    Nov 9, 2017 to Nov 10, 2017
    Prague

  73. Aspects Impacting Virus Filter Selection for Cell Culture-Based Biomanufacturing Processes

    Sven Schubert, Senior Process Manager, DSP Process Design / Validation, Rentschler Biopharma SE
    20th Planova™ Workshop
    Nov 9, 2017 to Nov 10, 2017
    Prague

  74. Impact of Prefilter and Operating Parameters on Virus Filter Performance

    Sean O'Donnell, Principal Research Scientist, Virology and Purification Development, Eli Lilly and Company
    20th Planova™ Workshop
    Nov 9, 2017 to Nov 10, 2017
    Prague

  75. Evaluation of Pre-Filtration on BioEX Process Performance for Monoclonal Antibodies

    Ashlee Smith, Associate Scientist, API-Large Molecule, Janssen Research and Development
    20th Planova™ Workshop
    Nov 9, 2017 to Nov 10, 2017
    Prague

  76. Viral Filtration of a Therapeutic Monoclonal Antibody: Impact of Clarification Impurities

    Hendri Tjandra, Senior Staff Scientist, Drug Discovery - Biologics Development, Bayer
    20th Planova™ Workshop
    Nov 9, 2017 to Nov 10, 2017
    Prague

  77. Validation of Planova™ 20N as an Alternative Virus Reduction Filter for a Commercial Product

    Denis P. Twomey, Principal Scientist Pharmaceutical Development and Manufacturing Sciences, Janssen Sciences Ireland UC
    20th Planova™ Workshop
    Nov 9, 2017 to Nov 10, 2017
    Prague

  78. Downscaling a Manufacturing Process with Planova™ 20N Filters for Viral Clearance Study

    Javier Castrillo, Downstream Technician / Downstream Scientist, Process Development, mAbxience
    20th Planova™ Workshop
    Nov 9, 2017 to Nov 10, 2017
    Prague

  79. High Capacity Filtration: Biotest Next Level, a New Plant to Manufacture a Human Immunoglobulin G Preparation with Removal of Viruses by a Planova™ BioEX Filtration

    Marcel Asper / Michael Rodemer, Director, Virus Laboratory, Pathogen Safety / Director, Project Manager, BNL,Biotest
    20th Planova™ Workshop
    Nov 9, 2017 to Nov 10, 2017
    Prague

  80. Upstream Virus Barriers: Why and How

    Andreas Wieser, Senior Laboratory Associate Global Pathogen Safety, Shire
    20th Planova™ Workshop
    Nov 9, 2017 to Nov 10, 2017
    Prague

  81. Challenges of Implementing Virus Filtration into Continuous Manufacturing

    Daniel Strauss, Principal Scientist, R&D, Asahi Kasei Bioprocess America
    20th Planova™ Workshop
    Nov 9, 2017 to Nov 10, 2017
    Prague

  82. Planova™ History in Technological Innovation Recognized in Virus Removal Filter

    Seiichi Manabe, Head of a Technical Adviser Office, Manabe Gijutsushi Jimusho
    20th Planova™ Workshop
    Nov 9, 2017 to Nov 10, 2017
    Prague

  83. Process evaluation and search for devices for prion removal using mouse adapted vCJD

    Oscar Jun Adan-Kubo, Research Scientist, Infectious Pathogen Research Group, R&D, Benesis Corporation
    15th Planova™ Workshop
    Jun 14, 2012 to Jun 15, 2012
    Boston

  84. Experience with Reduction of Small Non-enveloped Viruses

    Johannes Blümel, Head of virus safety section, Paul Ehrlich Institute
    14th Planova™ Workshop
    Nov 9, 2011 to Nov 10, 2011
    Cologne

  85. Understanding Planova™ Virus Filtration and Designing Robust Virus Filtration Processes

    Tomoko Hongo-Hirasaki, Senior Scientist, Group Manager of Evaluation and Analysis, Asahi Kasei Medical
    20th Planova™ Workshop
    Nov 9, 2017 to Nov 10, 2017
    Prague

  86. Process Development for High Concentration Mab with Planova™ BioEX Filter

    Roy Kahn, Researcher, DSP Process Development, InSight Biopharmaceuticals Ltd.
    2nd Planova™ Workshop in India
    Feb 9, 2017
    Goa

  87. Design of Experiment (DoE) Applied to the Optimization of the Filtration of FVIII on a 20-20 nm Planova™ Filters Sequence. Demonstration of the Step Robustness and Implementation into the LFB FVIII Manufacturing Process

    Michel POULLE, Head of Process Laboratory, Industrial Support Unit, Department of Industrial Processes, LFB Biomedicaments
    18th Planova™ Wokshop
    Oct 22, 2015 to Oct 23, 2015
    Athens

  88. Process Development for High Concentration Mab with Planova™ BioEX Filter

    Roy KAHN, Researcher, DSP, Process Development, InSight Biopharmaceuticals Ltd
    18th Planova™ Wokshop
    Oct 22, 2015 to Oct 23, 2015
    Athens

  89. Implementation of the Planova™ Virus Reduction Filter into an Established Manufacturing Process

    Andrew Griffiths, Scientist, Process Support, Biosciences, Emergent BioSolutions
    17th Planova™ Workshop
    Jun 12, 2014 to Jun 13, 2014
    Washington, D.C.

  90. Clarification of Cell Culture Supernatant Using BioOptimal™ MF-SL Modules in Early-Stage R&D

    Yuichiro Shimizu,Researcher,ChugaiPharmabody Research
    17th Planova™ Workshop
    Jun 12, 2014 to Jun 13, 2014
    Washington, D.C.

  91. Combining Planova™ Filters in Series Provides a Synergistic Enhancement of Viral Clearance Capability While Mitigating Process Risks

    Daniel Strauss, Senior Scientist, Science and Technology, AsahiKasei Bioprocess
    17th Planova™ Workshop
    Jun 12, 2014 to Jun 13, 2014
    Washington, D.C.

  92. Process Development and Scale-Up of MABp1 Using Planova™ 20N and QyuSpeedTM D

    Josh Combs,Vice President, Manufacturing,XBiotech
    17th Planova™ Workshop
    Jun 12, 2014 to Jun 13, 2014
    Washington, D.C.

  93. VRF: The UCB Experience

    Nicola Humpherson,Principal Scientist, Downstream Process Sciences,UCB
    17th Planova™ Workshop
    Jun 12, 2014 to Jun 13, 2014
    Washington, D.C.

  94. Planova™ 35N Nanofiltration of a Plasma-Derived Immune Globulin Product

    BarryGooch, Senior Research Scientist II, R&D, Pathogen Safety,Grifols
    17th Planova™ Workshop
    Jun 12, 2014 to Jun 13, 2014
    Washington, D.C.

  95. Interruption of Filtration and Residual Virus in the Filtrate

    Herbert Dichtelmüller, President, ViruSafe-Consult
    17th Planova™ Workshop
    Jun 12, 2014 to Jun 13, 2014
    Washington, D.C.

  96. Process Designing for Virus Removal Filtration

    Tomoko Hongo-Hirasaki,Manager, Bioprocess Technology Development Department,Asahi Kasei Medical
    17th Planova™ Workshop
    Jun 12, 2014 to Jun 13, 2014
    Washington, D.C.

  97. Virus Filter Breakthrough Modes and Risk Mitigation Strategies

    Kurt Brorson, Scientist, CDER, FDA
    17th Planova™ Workshop
    Jun 12, 2014 to Jun 13, 2014
    Washington, D.C.

  98. Virus Removal is Affected by Flux, Brownian Motion of Virus and Virus-Membrane Interaction

    Oscar Jun Adan-Kubo, Lead Researcher, Protein Pharmacology Research Section, Japan Blood Products Organization
    17th Planova™ Workshop
    Jun 12, 2014 to Jun 13, 2014
    Washington, D.C.

  99. Determination of Viral Clearance Design Spaces on Planova™ 20N and BioEX Filters

    Josh Goldstein, Scientist, Pharmaceutical Development and Manufacturing Sciences, Janssen Research & Development
    17th Planova™ Workshop
    Jun 12, 2014 to Jun 13, 2014
    Washington, D.C.

  100. New Planova™ Oita Plant for Secure Global Supply Chain

    Shuji Fujita, Manager,Asahi Kasei Medical Co., Ltd.
    16th Planova™ Workshop
    Nov 7, 2013 to Nov 8, 2013
    Rome

  101. Bispecific Antibody Purification and Virus Filtration Challenges

    Germano Coppola,Associate Director, Process Sciences,Abbvie Bioresearch Centre Inc.
    16th Planova™ Workshop
    Nov 7, 2013 to Nov 8, 2013
    Rome

  102. Introduction of Automated Planova™ Filtration Systems at Janssen Biologics B.V.

    Guido Ragetlie, Principal Engineer, Janssen Biologics B.V.
    16th Planova™ Workshop
    Nov 7, 2013 to Nov 8, 2013
    Rome

  103. Robust Strategy Development for Primary Recovery of High Cell Density Mammalian Cell Cultures Using Ultra Scale-Down Models

    Daria Popova, Research Engineer, Department of Biochemical Engineering, University College London
    16th Planova™ Workshop
    Nov 7, 2013 to Nov 8, 2013
    Rome

  104. Panel Disucussion: Parvovirus Retentive Properties of Planova™ Filters under Various Conditions - Process Interruption and Pressure Level -

    Dr. Herbert Dichtelmueller with Dr. Bluemel, Dr. Kreil, Mr. Nothelfer, Dr. Hongo, Mr. Sato, Dr. Ruppach, Dr.Bailey
    16th Planova™ Workshop
    Nov 7, 2013 to Nov 8, 2013
    Rome

  105. Characteristics and Optimum Selection of Planova™ Virus Removal Filters

    Tomoko Hongo-Hirasaki, Manager, Asahi Kasei Medical Co., Ltd.
    16th Planova™ Workshop
    Nov 7, 2013 to Nov 8, 2013
    Rome

  106. Virus Filtration and Biotechnology Processes

    Thomas Kreil,Associate Professor of Virology, Senior Director Global Pathogen Safety, Baxter BioScience
    16th Planova™ Workshop
    Nov 7, 2013 to Nov 8, 2013
    Rome

  107. Large Volume Filtration with Novel Virus Preparation Method

    Kazuya Kobayashi, R&D Staff, Asahi Kasei Medical Co., Ltd.
    16th Planova™ Workshop
    Nov 7, 2013 to Nov 8, 2013
    Rome

  108. lmprovements in Down-scaling of Virus Filtration

    Andreas Wieser,Senior Laboratory Associate,Global Pathogen Safety, Baxter BioScience
    16th Planova™ Workshop
    Nov 7, 2013 to Nov 8, 2013
    Rome

  109. Process Improvement, Virus Removal Data and Regulatory Background for Changing a Nanofilter of F-IX Product.

    Regina Voges-Haas, Head of Laboratory Development Plasma Proteins, Biotest AG
    16th Planova™ Workshop
    Nov 7, 2013 to Nov 8, 2013
    Rome

  110. Application of Planova™ Virus Filters in Recombinant Protein and mAb Purification Processes - Process Performance and Viral Removal Data -

    Franz Nothelfer, Associate Director, Protein Science, Boehringer Ingelheim Pharma GmbH & Co. KG
    16th Planova™ Workshop
    Nov 7, 2013 to Nov 8, 2013
    Rome

  111. Nanofiltration in Plasma-derived IVIG - Process Design for Full Scale Production

    Alessandra Lazzarotti, Scientist, Industrial Development & Research, Kedrion Biopharma S.p.A.
    16th Planova™ Workshop
    Nov 7, 2013 to Nov 8, 2013
    Rome

  112. Development of Viral Filtration Process for Monoclonal Antibody

    Lalit Saxena, Manager, Production, Mabpharm Private Limited
    1st Planova™ Workshop in India
    Jan 31, 2013
    Goa

  113. Asahi Product Development Concept

    Terry Sato/Hironobu Shirataki, General Manager/Global Product Manager, Asahi Kasei Medical Co., Ltd.
    1st Planova™ Workshop in India
    Jan 31, 2013
    Goa

  114. Development of a Viral Filtration Step

    Erich Blatter, Senior Scientist, Purification Sciences Human Genome Sciences, Inc.
    15th Planova™ Workshop
    Jun 14, 2012 to Jun 15, 2012
    Boston

  115. Scale-Up of Planova™ 20N Filtration for Commercial Production of Monoclonal Antibodies Using a Platform Approach

    Tom Belval, Principal Engineer, Global Process Engineering, Amgen
    15th Planova™ Workshop
    Jun 14, 2012 to Jun 15, 2012
    Boston

  116. Implementation of Automatic Cleaning and Integrity Testing of Planova™ Filters at Sanquin Plasma Products

    J.F. van de Laar, Plasma Products, Dept. of Process Support and Development, Sanquin
    14th Planova™ Workshop
    Nov 9, 2011 to Nov 10, 2011
    Cologne

  117. Use of In-house Platform Data to Support Reduced Viral Clearance Validation

    Stefan Hepbildikler, Director, Recovery & Downstream Processing C, Roche Pharma Biotech Development
    14th Planova™ Workshop
    Nov 9, 2011 to Nov 10, 2011
    Cologne

  118. Process Designing for Virus Removal Filter

    Tomoko Hongo-Hirasaki, Manager, Technology Development Department, Asahi Kasei Medical Co., Ltd.
    14th Planova™ Workshop
    Nov 9, 2011 to Nov 10, 2011
    Cologne

  119. Comparison of Downscale and Process Virus Retentive Filter

    Marcel Asper, Study Director, Charles River Biopharmaceutical Services GmbH
    14th Planova™ Workshop
    Nov 9, 2011 to Nov 10, 2011
    Cologne

  120. Selection of a Virus Filter for a Plasma Product

    Shirley Stagg, Senior Project Scientist, Biosafety and Product Development, Bio Products Laboratory Ltd.
    14th Planova™ Workshop
    Nov 9, 2011 to Nov 10, 2011
    Cologne

  121. The Goal of Increasing Safety in Different Plasma Derivative Manufacturing Processes: 15 Years Experience of Grifols with Planova™ Nanofiltration

    Santiago Caballero, Santiago Caballero, Ph.D., Instituto Grifols, S.A.
    14th Planova™ Workshop
    Nov 9, 2011 to Nov 10, 2011
    Cologne

  122. Removal Capacity of Transmissible Spongiform Encephalopathy (TSE) Model Agents in Plasma Products. Nanofiltration Contribution.

    Francisco J. Belda, Head Virology Section, Instituto Grifols S.A.
    16th Planova™ Workshop
    Nov 7, 2013 to Nov 8, 2013
    Rome